Trial Profile

A placebo-controlled double-blind phase II clinical trial assessing IRX4204 in Parkinsons disease

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 20 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IRX 4204 (Primary)
Indications Parkinson's disease
Focus Adverse reactions; Therapeutic Use

Most Recent Events

18 Sep 2024 According to Io Therapeutics media release, company is planning a placebo-controlled double-blind phase II clinical trial of IRX4204 in Parkinsons disease, to be initiated in Q1 of 2025.
15 Jul 2024 New trial record
09 Jul 2024 According to Io Therapeutics, Inc., media release, company is planning to initiate a placebo-controlled phase II clinical trial of IRX4204 in Parkinsons disease patients in Q4 of 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com